Last reviewed · How we verify
Zolpidem CR
Zolpidem CR is a Non-benzodiazepine hypnotic (Z-drug) Small molecule drug developed by Henry Ford Health System. It is currently FDA-approved for Insomnia (sleep onset and sleep maintenance). Also known as: Ambian CR, Ambien CR.
Zolpidem CR is a sedative-hypnotic that binds to GABA-A receptors in the brain to promote sleep onset and maintenance.
Zolpidem CR is a sedative-hypnotic that binds to GABA-A receptors in the brain to promote sleep onset and maintenance. Used for Insomnia (sleep onset and sleep maintenance).
At a glance
| Generic name | Zolpidem CR |
|---|---|
| Also known as | Ambian CR, Ambien CR |
| Sponsor | Henry Ford Health System |
| Drug class | Non-benzodiazepine hypnotic (Z-drug) |
| Target | GABA-A receptor (alpha-1 subunit selective) |
| Modality | Small molecule |
| Therapeutic area | Neurology / Sleep Medicine |
| Phase | FDA-approved |
Mechanism of action
Zolpidem is a non-benzodiazepine hypnotic (Z-drug) that selectively binds to alpha-1 subunit-containing GABA-A receptors, enhancing the inhibitory effects of GABA and depressing central nervous system activity. The controlled-release formulation provides immediate release for sleep onset followed by sustained release for sleep maintenance throughout the night.
Approved indications
- Insomnia (sleep onset and sleep maintenance)
Common side effects
- Dizziness
- Drowsiness/somnolence
- Headache
- Complex sleep behaviors
- Hallucinations
- Memory impairment
Key clinical trials
- Efficacy and Safety of APSTZD in the Treatment of Insomnia Disorder (PHASE2)
- The Study in Outpatient Medicine Using Nudges to Improve Sleep (NA)
- Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1) (PHASE3)
- Safety and Efficacy of Chronic Hypnotic Use 2 (PHASE4)
- Reducing Suicidal Ideation Through Insomnia Treatment (PHASE4)
- Polysomnographic Study Comparing the Use of Dexmedetomidine and Zolpidem to Induce Natural Sleep (NA)
- The Role of Sleep in the Treatment of Cannabis Use Disorders (PHASE2, PHASE3)
- Zolpidem CR and Hospitalized Patients With Dementia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zolpidem CR CI brief — competitive landscape report
- Zolpidem CR updates RSS · CI watch RSS
- Henry Ford Health System portfolio CI
Frequently asked questions about Zolpidem CR
What is Zolpidem CR?
How does Zolpidem CR work?
What is Zolpidem CR used for?
Who makes Zolpidem CR?
Is Zolpidem CR also known as anything else?
What drug class is Zolpidem CR in?
What development phase is Zolpidem CR in?
What are the side effects of Zolpidem CR?
What does Zolpidem CR target?
Related
- Drug class: All Non-benzodiazepine hypnotic (Z-drug) drugs
- Target: All drugs targeting GABA-A receptor (alpha-1 subunit selective)
- Manufacturer: Henry Ford Health System — full pipeline
- Therapeutic area: All drugs in Neurology / Sleep Medicine
- Indication: Drugs for Insomnia (sleep onset and sleep maintenance)
- Also known as: Ambian CR, Ambien CR
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing